Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

Mise à jour : Il y a 4 ans
Référence : NCT00279760

Femme et Homme

Extrait

This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA


Critère d'inclusion

  • Rheumatoid Arthritis


Liens